Cerevance is at the forefront of developing innovative therapies for central nervous system (CNS) disorders, leveraging its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform. This technology enables the molecular analysis of specific cell types within human brain tissue, allowing for the identification of novel therapeutic targets that are either uniquely expressed in certain brain circuits or exhibit altered expression in diseased states. By utilizing this advanced approach, Cerevance aims to uncover critical pathways and receptors involved in neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis (ALS), thereby facilitating the development of targeted treatments.

The company’s pipeline includes several promising candidates, such as CVN424, a first-in-class, non-dopaminergic therapy for Parkinson’s disease that targets the GPR6 receptor, and CVN293, which aims to modulate neuroinflammation in ALS and Alzheimer’s. These therapies are designed to provide significant clinical benefits while minimizing common side effects associated with traditional dopaminergic treatments. Cerevance's commitment to advancing its robust clinical pipeline is further supported by strategic collaborations with major pharmaceutical companies, enhancing its capacity to deliver innovative solutions for patients suffering from debilitating CNS disorders.

United States

Cerevance is a revolutionary pharmaceutical company using the proprietary NETSseq platform to develop novel symptomatic and therapeutic treatments for central nervous system (CNS) disorders.

Cerevance

Company Details